Immune Design starts dosing patients in Phase I study of LV305 immuno-oncology agent
US-based Immune Design has started dosing patients in a Phase I clinical study of LV305, an immuno-oncology investigational agent from ...
US-based Immune Design has started dosing patients in a Phase I clinical study of LV305, an immuno-oncology investigational agent from ...
On Friday, June 06, 2014, the NASDAQ Composite ended at 4,321.40, up 0.59%, the Dow Jones Industrial Average finished the ...
US-based biotechnology firm Edge Therapeutics has started enrolling patients in the second group of a multicenter, randomised, controlled, open-label, Phase ...
US-based Arena Pharmaceuticals has started dosing patients in an investigational Phase Ib clinical trial of APD334, an oral drug candidate ...
US-based Boston Therapeutics (BTI) has started a Phase IIb clinical trial SD-002 to evaluate the efficacy and safety of Sugardown ...
Veterans trying to schedule medical appointments in the Veterans Affairs Department’s Phoenix Health Care System entered a Kafkaesque world where ...
GAINESVILLE, Fla. — At the conclusion of the first year of UF Health’s Personalized Medicine Program, the results are in: ...
US-based Alexion Pharmaceuticals has started a single, multinational, placebo-controlled trial designed to assess the safety and efficacy of eculizumab (Soliris) ...
US-based drug maker Pfizer has confirmed that it has contacted AstraZeneca seeking to renew discussions over a possible £60bn takeover. ...
Eli Lilly has obtained US Food and Drug Administration approval for its Cyramza (ramucirumab) as a single-agent treatment for patients ...
Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.